摘要 |
<p>The polyheteroaryl derivatives of the invention are penta-, hexa-, hepta-, octa-, nona- and deca-heteroaryl (abbreviated hereafter as penta- to deca-heteroaryl) structurally are characterized by a combination of heterocycle 1 (Het-1) a and/or heterocycle 2 (Het-2) b and/or heterocycle 3 (Het-3) c and/or heterocycle 4 (Het-4) d of formulae I, II, III and IV respectively,
the N-oxides, the pharmaceutically acceptable addition salts.
The compounds claimed are suitable for anti-cancer agents.</p> |